Where it comes from
- Made in
- L cells of the lower gut
- Sent out by
- After a meal, in proportion to its size; rises greatly after gastric bypass
- Acts on
- Hypothalamus
- Pancreas
- Liver
What it does
In medicine
Beyond the body’s own use
- It is the template for the GLP-1/glucagon dual agonists: mazdutide took off 16.7% of body weight in a Chinese phase 3 trial 3 and is approved there for weight management, survodutide is in phase 3 for obesity and fatty liver disease, and cotadutide was dropped
- Infused into volunteers four days running it both cut energy intake and raised energy expenditure, which is the finding the whole dual-agonist idea rests on 1
- Oxyntomodulin itself lasts minutes in blood, so it is given only by infusion in a study; the medicines built from it are engineered to last a week
Sources
- Wynne et al., Oxyntomodulin increases energy expenditure and decreases energy intake, International Journal of Obesity 2006
- Perakakis et al., The role of glicentin and oxyntomodulin in human metabolism, Journal of Clinical Endocrinology and Metabolism 2020
- Gao et al., Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2), JAMA 2026
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.